BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25468813)

  • 1. Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors.
    Kwon MJ; Shin HS; Nam ES; Cho SJ; Lee MJ; Lee S; Park HR
    Pathol Res Pract; 2015 May; 211(5):349-55. PubMed ID: 25468813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
    Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
    Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.
    Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT
    Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.
    Jayaraj P; Sen S; Sharma A; Chosdol K; Kashyap S; Rai A; Pushker N; Bajaj MS; Ghose S
    Br J Dermatol; 2012 Sep; 167(3):583-90. PubMed ID: 22458737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cell cycle regulatory proteins in eyelid sebaceous gland carcinoma: low p27 expression predicts poor prognosis.
    Kim N; Kim JE; Choung HK; Lee MJ; Khwarg SI
    Exp Eye Res; 2014 Jan; 118():46-52. PubMed ID: 24216315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53.
    Gonzalez-Fernandez F; Kaltreider SA; Patnaik BD; Retief JD; Bao Y; Newman S; Stoler MH; Levine PA
    Ophthalmology; 1998 Mar; 105(3):497-506. PubMed ID: 9499782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.
    Yunoki T; Hirano T; Tabuchi Y; Furusawa Y; Torigoe M; Nakajima T; Imura J; Hayashi A
    Int Ophthalmol; 2020 Feb; 40(2):343-350. PubMed ID: 31571090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid.
    Kiyosaki K; Nakada C; Hijiya N; Tsukamoto Y; Matsuura K; Nakatsuka K; Daa T; Yokoyama S; Imaizumi M; Moriyama M
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):7-11. PubMed ID: 19628749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
    Sińczak-Kuta A; Tomaszewska R; Rudnicka-Sosin L; Okoń K; Stachura J
    Pol J Pathol; 2007; 58(1):41-50. PubMed ID: 17585541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Whole-Exome and Transcriptome Sequencing Indicated Dysregulation of Cholesterol Metabolism in Eyelid Sebaceous Gland Carcinoma.
    Wang Y; Li J; Hao P; Li J; Han R; Lin J; Li X
    Transl Vis Sci Technol; 2023 Feb; 12(2):4. PubMed ID: 36735267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sebaceous neoplasms: prevalence of HPV infection and relation to immunohistochemical surrogate markers.
    Saliba M; Shaheen M; El Hajj R; Abbas FI; Bashir S; Sheikh UNN; Mahfouz R; Loya A; Khalifeh I
    Eur J Dermatol; 2021 Apr; 31(2):170-175. PubMed ID: 34001468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
    Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
    Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
    Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
    Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
    Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
    Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.